Abstract
Objective
To analyze changes in ganglion cell complex (GCC) thickness in wet age-related macular
degeneration (AMD) patients receiving intravitreal injections.
Design
Retrospective cohort study involving 46 eyes at a single tertiary ophthalmology practice.
Participants
The injection group consisted of wet AMD patients who received intravitreal injections
for at least 3 years following a treat-and-extend protocol. Twenty-two patients received
ranibizumab, and 1 patient received aflibercept. The control group consisted of dry
AMD patients who were observed only and did not receive medical treatment over the
same period. GCC thickness and visual acuity were recorded at baseline and at 1-,
2-, and 3-year follow-up visits.
Results
In the injection group, there was a nonsignificant trend toward reduction in GCC thickness
over 3 years (–4.09 ± 8.47 µm; p = 0.09). Within the injection group, correlation analysis between the number of intravitreal
injections and GCC thickness was nonsignificant but trended toward a direct relationship,
with more injections correlated with a relatively thicker GCC at 3 years. There was
no significant change in GCC thickness between baseline and year 3 for the control
group.
Conclusions
Study results suggest that that there is no significant GCC thinning in wet AMD patients
following a treat-and-extend regimen over 3 years.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of OphthalmologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Age-related macular degeneration.Retina. 2009; 29: S2-S4
- Associations between cardiovascular risk factors and early age-related macular degeneration in a rural chinese adult population.Retina. 2014; 34: 1539-1553
Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol. 39:367–74.
- Preservation of ganglion cell layer neurons in age-related macular degeneration.Invest Ophthalmol Vis Sci. 2001; 42: 795-803
- Age-related macular degeneration.N Engl J Med. 2008; 358: 2606-2617
- Intravitreal injection of dexamethasone implant in serous macular detachment associated with Waldenström's DISEASE.Case Rep Ophthalmol. 2013; 4: 64-69
- Intravitreal bevacizumab in the successful management of choroidal metastases secondary to lung and breast cancer unresponsive to systemic therapy: a case series.Eye (Lond). 2014; 28: 888-891
- Intravitreal ranibizumab and laser photocoagulation in the management of idiopathic juxtafoveolar retinal telangiectasia type 1: a case report.Case Rep Ophthalmol. 2012; 3: 298-303
- Ranibizumab for neovascular age-related macular degeneration.N Engl J Med. 2006; 355: 1419-1431
- An update on intravitreal implants in use for eye disorders.Drugs Today (Barc). 2014; 50: 239-249
- Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.Ophthalmology. 2006; 113 (e5): 363-372
- Pegaptanib (Macugen): treating neovascular age-related macular degeneration and current role in clinical practice.Ophthalmol Clin North Am. 2006; 19: 353-360
- VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection.BioEssays. 2004; 26: 943-954
- Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections.Ophthalmology. 2012; 119: 321-326
- Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents.Br J Ophthalmol. 2011; 95: 1111-1114
- Utility of ganglion cell complex analysis in early diagnosis and monitoring of glaucoma using a different spectral domain optical coherence tomography.J Curr Glaucoma Pract. 2014; 8: 101-106
- Diagnostic validity of macular ganglion cell–inner plexiform layer thickness deviation map algorithm using Cirrus HD-OCT in preperimetric and early glaucoma.J Glaucoma. 2014; 23: e144-e151
- Macular ganglion cell complex and retinal nerve fiber layer comparison in different stages of age-related macular degeneration.Am J Ophthalmol. 2015; 160 (e1): 602-607
- Retinal ganglion cell layer change in patients treated with anti–vascular endothelial growth factor for neovascular age-related macular degeneration.Am J Ophthalmol. 2016; 167: 10-17
- Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells.Mol Vis. 2010; 16: 1848-1853
- The effect of anti-vascular endothelial growth factor agents on intraocular pressure and glaucoma: a report by the American Academy of Ophthalmology.Ophthalmology. 2019; 126: 611-622
- N-Methyl-d-aspartate–induced neurotoxicity in the adult rat retina.Vis Neurosci. 1992; 8: 567-573
- Retrograde transneuronal degeneration in the retina and lateral geniculate nucleus of the V1-lesioned marmoset monkey.Brain Struct Funct. 2015; 220: 351-360
- Functional loss in early age-related maculopathy: the ischaemia postreceptoral hypothesis.Eye (Lond). 2007; 21: 689-696
- Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.Am J Pathol. 2007; 171: 53-67
- Effects of bevacizumab (Avastin) on retinal cells in organotypic culture.Invest Ophthalmol Vis Sci. 2008; 49: 3164
- Association of repeated intravitreous bevacizumab injections with risk for glaucoma surgery.JAMA Ophthalmol. 2017; 135: 363
- Ganglion cell–inner plexiform layer and peripapillary retinal nerve fiber layer thicknesses in age-related macular degeneration.Invest Ophthalmol Vis Sci. 2015; 56: 3976
- Quantitative analysis of the inner retinal layer thicknesses in age-related macular degeneration using corrected optical coherence tomography segmentation.Retina. 2018; 38: 1478-1484
- Ganglion cell complex evaluation in exudative age-related macular degeneration after repeated intravitreal injections of ranibizumab.BioMed Res Int. 2015; 2015268796
- Effect of intravitreal ranibizumab on ganglion cell complex and peripapillary retinal nerve fiber layer in neovascular age-related macular degeneration using spectral domain optical coherence tomography.Retina. 2017; 37: 1314-1319
- Intravitreal anti-vascular endothelial growth factor therapy and retinal nerve fiber layer loss in eyes with age-related macular degeneration: a meta-analysis.Invest Ophthalmol Vis Sci. 2016; 57: 1798
- Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab.Invest Ophthalmol Vis Sci. 2012; 53: 6214
- Macular ganglion cell complex changes in eyes treated with aflibercept for neovascular age-related macular degeneration.Photodiagnosis Photodyn Ther. 2021; 35102383
Article info
Publication history
Published online: December 16, 2022
Accepted:
November 26,
2022
Received in revised form:
November 15,
2022
Received:
December 29,
2021
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2022 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.
